

USERS MANUAL

HIV DRUG RESISTANCE

HIV DRUG RESISTANCE SURVEYS: TOOL FOR DATA ENTRY

DECEMBER 2017



HIV DRUG RESISTANCE SURVEYS: TOOL FOR DATA ENTRY

DECEMBER 2017

HIV drug resistance surveys: tool for data entry

ISBN 978-92-4-151207-7

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. HIV drug resistance surveys: tool for data entry. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland – for customs purposes

TABLE OF CONTENTS

Acronyms and Abbreviations	3
1. Introduction	4
2. PDR site-level data entry tool	4
2.1 Before getting started	5
2.1.1 Naming site-level data entry files (naming convention)	5
2.1.2 Columns with data validation fields	5
2.1.3 Move the cursor to the right (optional)	5
2.2 Worksheet descriptions	5
2.2.1 Survey information worksheet	6
2.2.2 Configuration worksheet	6
2.2.3 Survey participants worksheet	7
2.2.3.1 Site code	7
2.2.3.2 Participant ID	7
2.2.3.3 Prior drug(s) exposure (Y/N/U)	7
2.2.3.4 Date screened	8
2.2.3.5 Enrolled (Y/N)	8
2.2.3.6 Gender	8
2.2.3.7 Date of birth	9
2.2.3.8 Age	9
2.2.3.9 CD4 cell count	9
2.2.3.10 CD4 cell count date	10
2.2.3.11 Genotyping successful	10
2.2.3.12 Lab specimen code	10
2.2.4 Participant antiretroviral drug exposure worksheet	11
2.2.4.1 Participant ID	11
2.2.4.2 ART initiated (Y/N)	12
2.2.4.3 Type of prior ARV drug exposure	12
2.2.4.4 Type of PMTCT exposure	12
2.2.4.5 ARV drug exposure(s)	13
2.2.4.6 Other ARV drug exposure	13
3. PDR National-level template: Data consolidator tool	14
3.1 Before getting started	14
3.1.1 Naming national data consolidator file (naming convention)	14
3.1.2 Enable macros	15
3.2 "List" worksheet	15
3.2.1 STEP 1	16
3.3 Survey participants worksheet	17
3.3.1 STEP 2	17
3.4 Participant ARV drug exposure worksheet	19
3.4.1 STEP 3	19

4. ADR site-level data entry tool	20
4.1 Before getting started	21
4.1.1 Naming site-level data entry files (naming convention)	21
4.1.2 Columns with data validation fields	21
4.1.3 Move the cursor to the right (optional)	21
4.2 Worksheets description	22
4.2.1 Survey information worksheet	22
4.2.2 Configuration worksheet	23
4.2.3 Survey participants worksheet	23
4.2.3.1 Site code	23
4.2.3.2 Participant ID	24
4.2.3.3 Date of first ART initiation	24
4.2.3.4 Date screened	24
4.2.3.5 Enrolled (Y/N)	25
4.2.3.6 Gender	25
4.2.3.7 Date of birth	26
4.2.3.8 Age	26
4.2.3.9 Current ART line	26
4.2.3.10 Viral load result	27
4.2.3.11 Viral load value (copies/mL)	27
4.2.3.12 Genotyping successful	27
4.2.3.13 Lab specimen code	28
4.2.4 Participant antiretroviral drug worksheet	28
4.2.4.1 Participant ID	28
4.2.4.2 ARV drug	29
4.2.4.3 Other ARV drug	29
4.2.4.4 Current ART (Y/N)	29
4.2.4.5 Date started	30
4.2.4.6 ART line	30
5. ADR national-level template: Data consolidator tool	30
5.1 Before getting started	31
5.1.1 Naming national data consolidator file (naming convention)	31
5.1.2 Enable macros	31
5.2 "List" worksheet	32
5.2.1 STEP 1	32
5.3 Worksheet survey participants	33
5.3.1 STEP 2	34
5.4 Participant ARV drug worksheet	35
5.4.1 STEP 3	35

ACRONYMS AND ABBREVIATIONS

ADR	Acquired hiv drug resistance	PMTCT	Prevention of mother to child transmission
ART	Antiretroviral therapy	PEP	Post-exposure prophylaxis
ARV	Antiretroviral drug	PREP	Pre-exposure prophylaxis
AUQ	Above upper limit of quantification	SNA	Sequencing not attempted
BLQ	Below lower limit of quantification	SUC	Successfully sequenced
HIV	Human immunodeficiency virus	UNK	Unknown
IRQ	In range of quantification	UNS	Unsuccessfully sequenced
ISO	International organization for standardization	WHO	World health organization
PDR	Pre-treatment hiv drug resistance		

1. INTRODUCTION

Nationally representative surveillance of pre-treatment HIV drug resistance (PDR) in populations initiating antiretroviral therapy (ART) is critical to inform the selection of effective first-line ART, as well as appropriate regimens for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). Similarly, nationally representative surveillance of acquired HIV drug resistance (ADR) among populations failing ART provides critical information to assess programme efforts to maximize viral suppression, to inform selection and management of second-line therapies and to gauge the extent to which patients are switching therapies unnecessarily. The World Health Organization (WHO) recommends that countries routinely conduct national surveys of PDR and ADR.

To facilitate data collection at sites participating in PDR and ADR surveys, WHO has developed Excel-based Site-level Entry Tools. In addition, to support the management, analysis and reporting of national data, WHO has developed National Data Consolidator Tools for PDR and ADR surveys. These tools aggregate data from multiple Site-level Data Entry Tools into one national file. This manual provides instructions for using the PDR and ADR Site-level Data Entry Tools and the PDR and ADR National Data Consolidator Tools. These tools may be downloaded at the following website: <http://www.who.int/hiv/topics/drugresistance/en/>.

The intended audience for this manual is site-level data managers charged with collecting data for PDR and ADR surveys and national-level data managers and HIV drug resistance (HIVDR) technical working groups implementing HIVDR surveillance.

This instruction manual is divided into five sections:

- Section 1 is this introduction to the manual;
- Section 2 provides instructions for the PDR Survey Site-level Data Entry Tool;
- Section 3 provides instructions for the PDR National Data Consolidator Tool;
- Section 4 provides instructions for the ADR Survey Site-level Data Entry Tool;
- Section 5 provides instructions for the ADR National Data Consolidator Tool.

2. PDR SITE-LEVEL DATA ENTRY TOOL

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_26131

